Literature DB >> 11763248

Efficacy results and quality-of-life measures in men receiving sildenafil citrate for the treatment of erectile dysfunction.

F Giuliano1, B M Peña, A Mishra, M D Smith.   

Abstract

The aim of the present study was to evaluate the efficacy of sildenafil citrate and its effects on quality of life (QoL) in men with erectile dysfunction (ED) using data from three multicenter, double-blind, placebo-controlled clinical trials. Efficacy was evaluated using a global efficacy question (improvement of erections) and questions from the International Index of Erectile Function (IIEF) addressing the ability to achieve and maintain erections. QoL directly related to ED was evaluated using questions 13 and 14 of the IIEF, several psychometric instruments, and a questionnaire addressing men's concerns about their erection problems. Seventy-nine [corrected] percent of patients receiving sildenafil reported improved erections compared with 23% of patients receiving placebo (p < 0.0001); also reported were improvements in the ability to achieve and maintain erections with sildenafil but not with placebo (p < 0.0001). Improvements were also seen for other aspects of sexual function (overall satisfaction with sex life, sexual relationships with partners, concerns about erectile problems, p < 0.0001) and general mental health (well-being, self-control, satisfaction with relationship, health relative to 1 year ago, mental health; p < or = 0.05) following treatment with sildenafil. Thus, treatment of ED with sildenafil can significantly improve key QoL parameters related to sexual dysfunction and general mental health.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11763248     DOI: 10.1023/a:1012270220064

Source DB:  PubMed          Journal:  Qual Life Res        ISSN: 0962-9343            Impact factor:   4.147


  33 in total

1.  On life satisfaction in male erectile dysfunction.

Authors:  A R Fugl-Meyer; G Lodnert; I B Bränholm; K S Fugl-Meyer
Journal:  Int J Impot Res       Date:  1997-09       Impact factor: 2.896

2.  The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection.

Authors:  J E Ware; C D Sherbourne
Journal:  Med Care       Date:  1992-06       Impact factor: 2.983

3.  Efficacy and safety of oral sildenafil in the treatment of erectile dysfunction: a double-blind, placebo-controlled study of 329 patients. Sildenafil Study Group.

Authors:  H Padma-Nathan; W D Steers; P A Wicker
Journal:  Int J Clin Pract       Date:  1998-09       Impact factor: 2.503

4.  Quality of life effects of alprostadil therapy for erectile dysfunction.

Authors:  R J Willke; H A Glick; T J McCarron; M H Erder; S E Althof; O I Linet
Journal:  J Urol       Date:  1997-06       Impact factor: 7.450

5.  Effects of sildenafil on the relaxation of human corpus cavernosum tissue in vitro and on the activities of cyclic nucleotide phosphodiesterase isozymes.

Authors:  S A Ballard; C J Gingell; K Tang; L A Turner; M E Price; A M Naylor
Journal:  J Urol       Date:  1998-06       Impact factor: 7.450

6.  The MOS short-form general health survey. Reliability and validity in a patient population.

Authors:  A L Stewart; R D Hays; J E Ware
Journal:  Med Care       Date:  1988-07       Impact factor: 2.983

Review 7.  NIH Consensus Conference. Impotence. NIH Consensus Development Panel on Impotence.

Authors: 
Journal:  JAMA       Date:  1993-07-07       Impact factor: 56.272

8.  Cross-cultural development of a quality of life measure for men with erection difficulties.

Authors:  T H Wagner; D L Patrick; S P McKenna; P S Froese
Journal:  Qual Life Res       Date:  1996-08       Impact factor: 4.147

9.  The effect of transurethral alprostadil on the quality of life of men with erectile dysfunction, and their partners. MUSE Study Group.

Authors:  G Williams; C C Abbou; E T Amar; P Desvaux; T A Flam; G A Lycklama à Nijeholt; S F Lynch; R J Morgan; S C Müller; H Porst; J P Pryor; P Ryan; U K Witzsch; M M Hall; V A Place; A P Spivack; L K Todd; N Gesundheit
Journal:  Br J Urol       Date:  1998-12

10.  Treatment of erectile dysfunction with sildenafil.

Authors:  L S Marks; C Duda; F J Dorey; M L Macairan; P B Santos
Journal:  Urology       Date:  1999-01       Impact factor: 2.649

View more
  6 in total

1.  Relationship between erectile function and sexual self-confidence: a path analytic model in men being treated with tadalafil.

Authors:  A Sontag; X Ni; S E Althof; R C Rosen
Journal:  Int J Impot Res       Date:  2013-07-18       Impact factor: 2.896

2.  Sex differences in response to tadalafil in pulmonary arterial hypertension.

Authors:  Stephen C Mathai; Paul M Hassoun; Milo A Puhan; Yi Zhou; Robert A Wise
Journal:  Chest       Date:  2015-01       Impact factor: 9.410

Review 3.  A comparative review of the options for treatment of erectile dysfunction: which treatment for which patient?

Authors:  Konstantinos Hatzimouratidis; Dimitrios G Hatzichristou
Journal:  Drugs       Date:  2005       Impact factor: 9.546

4.  A placebo-controlled, multicenter, randomized, double-blind, flexible-dose, two-way crossover study to evaluate the efficacy and safety of sildenafil in men with traumatic spinal cord injury and erectile dysfunction.

Authors:  Sureyya Ergin; Berrin Gunduz; Hatice Ugurlu; Koncuy Sivrioglu; Sema Oncel; Haydar Gok; Belgin Erhan; Funda Levendoglu; Ozlem Senocak
Journal:  J Spinal Cord Med       Date:  2008       Impact factor: 1.985

Review 5.  Environmental Factors-Induced Oxidative Stress: Hormonal and Molecular Pathway Disruptions in Hypogonadism and Erectile Dysfunction.

Authors:  Shubhadeep Roychoudhury; Saptaparna Chakraborty; Arun Paul Choudhury; Anandan Das; Niraj Kumar Jha; Petr Slama; Monika Nath; Peter Massanyi; Janne Ruokolainen; Kavindra Kumar Kesari
Journal:  Antioxidants (Basel)       Date:  2021-05-24

Review 6.  Sildenafil in the treatment of erectile dysfunction: an overview of the clinical evidence.

Authors:  Konstantinos Hatzimouratidis
Journal:  Clin Interv Aging       Date:  2006       Impact factor: 4.458

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.